ArticleEFSA journal. European Food Safety Authority2023
Statement on the risk assessment of maximum residue levels (MRLs) for oxamyl in view of consumer protection.
Article in EFSA journal. European Food Safety Authority, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The 2024 European Union report on pesticide residues in food.EFSA journal. European Food Safety Authority · 2026Article
- The 2023 European Union report on pesticide residues in food.EFSA journal. European Food Safety Authority · 2025Article
- The 2022 European Union report on pesticide residues in food.EFSA journal. European Food Safety Authority · 2024Article
- Statement on the risk assessment of maximum residue levels (MRLs) for oxamyl in view of consumer protection.EFSA journal. European Food Safety Authority · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In accordance with Article 43 of Regulation (EC) No 396/2005, the European Commission requested EFSA to perform a risk assessment of the existing maximum residues levels (MRLs) for oxamyl considering the new toxicological reference values. Additionally, if needed to ensure adequate consumer protection, lower limits of quantification (LOQs) than those currently established in the legislation should be proposed. EFSA performed various consumer exposure calculation scenarios, considering the risk assessment values as available for the existing uses of oxamyl and the lowering of LOQs for several plant and animal commodities as suggested by the European Union Reference Laboratories for Pesticide Residues (EURLs). Based on the results of the consumer exposure assessment calculated considering the risk assessment values for crops with authorised oxamyl uses and the existing EU MRLs at the LOQ for remaining commodities (scenario 1), chronic consumer intake concerns were identified for 34 diets. Acute exposure concerns were identified for a wide range of crops, including crops with currently authorised oxamyl uses: bananas, potatoes, melons, cucumbers, carrots, watermelons, tomatoes, courgettes, parsnips, salsifies and aubergines/eggplants. Under exposure calculation scenario 3, which considered lowering of all MRLs to the lowest analytically achievable limits of quantification, EFSA concludes that chronic consumer exposure concerns can still not be excluded. Similarly, acute consumer exposure concerns were identified for 16 commodities, including crops with known authorised uses: potatoes, melons, watermelons and tomatoes, even though for these crops a lower LOQ as proposed by the EURLs were considered. Further refinements of the calculated exposure at the current stage were not possible by EFSA, but EFSA identified a list of commodities for which a lower LOQ than routinely achievable is expected to significantly reduce the consumer exposure and for which a risk management decision is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.